Description: A groundbreaking approach to combat solid tumor cancers.
Problem: Addressing challenges in treating metastatic breast cancer.
Solution: Utilizing cell therapeutics showing promise in resistant cases.
Data: 60% of patients extended life in trials, with animal models reversing metastasis.
Impact: A potential game-changer in the quest for effective cancer treatment.
Technology: Mature cells reprogrammed into pluripotent stem cells.
Vision: Bringing hope to countless patients by curing solid tumors.
Scalability: The technology holds potential for global implementation.
Stage: Seeking Series B financing with a target of $25 million.
Capital: $45 million invested over 20 years.
Use of Funds: Investment drives production, commercialization, and market introduction.
Risk Factors: Acknowledges inherent risks in biotechnology.